DESTINY-Breast04: practice-changing results for HER2-low breast cancer

Clinical outcomes in women with metastatic HER2-low breast cancer in the real world

HER2-low expression in breast cancer

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated w...

ENHERTU Therapy: A Powerful New Cancer Treatment

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM

Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate

Remaining questions surrounding HER2-low breast cancer – how low can you go?

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Remaining questions regarding HER2-low breast cancer

TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastases

METASTATIC BREAST CANCER: ENHERTU STOPS THE SPREAD

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer pts

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBC

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

DESTINY-Breast06: determining HER2-(ultra)low status in HR+ mBC

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

HealthWatch: ENHERTU – Metastatic Breast Cancer Drug Grants Tica’s Wish (3/13/2023)

Remaining questions on the management of HER2-low breast cancer

Effectiveness of TDXD vs. Sacituzumab for ER+ Breast Cancer | Jane Meisel, MD | ASCO22 Updates